SecBot SecBot
8-K ·Filed Apr 8, 2026

NRIX

Nurix Therapeutics, Inc.
BEARISH
Impact 6/10
Horizonweeks Processed7mo ago SEC0001549595-26-000024
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

The significant year-over-year revenue decline and increased losses may pressure shares despite the company's strong cash position and ongoing clinical advancements. Investors should monitor upcoming clinical data readouts and potential partnership renewals.

DirectionBearish
Confidencehigh
Horizonweeks

Price Chart

Loading chart...

Executive Summary

Nurix Therapeutics reported Q1 2026 financial results with revenue of $6.3 million, down from $18.5 million in the prior year quarter, and a net loss per share of $0.79. The company continues to advance its bexobrutideg clinical program while maintaining a $540.7 million cash position.

Key Financial Metrics

EPS
−$0.79
est −$0.76 · -4.0%
Revenue
$6.3M
est $14.2M · -55.6% · -66.0% YoY
Rating
miss

Key Facts

  • Revenue for Q1 2026 was $6.3 million, down from $18.5 million in Q1 2025
  • Net loss was $87.2 million, or $0.79 per share, compared to $56.4 million, or $0.67 per share, in the prior year quarter
  • Cash, cash equivalents and marketable securities were $540.7 million as of February 28, 2026
  • Research and development expenses increased to $84.1 million from $69.7 million in the prior year quarter
  • The decrease in revenue was primarily due to the conclusion of the initial research term for certain drug targets with Sanofi

Financial Impact

Revenue decreased by $12.2 million year-over-year, with increased R&D spending contributing to larger net loss

revenuenet losscash positionR&D expenses

Risk Factors

  • Continued revenue decline as collaboration agreements conclude
  • Increasing R&D expenses without near-term commercial products
  • Dependence on successful clinical trial outcomes for future value creation

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001549595-26-000024
Document: nrix-20260408.htm0001549595-26-000024
Document: 0001549595-26-000024-index-headers.html0001549595-26-000024
Document: 0001549595-26-000024-index.html0001549595-26-000024
Document: 0001549595-26-000024.txt0001549595-26-000024
8-K Data (Synthetic)0001549595-26-000024

Track record

33 reports on NRIX

Performance horizon

4 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +53.71% at T+20 after the Jun 8, 2026 report. 6 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $14.67 Now $14.73 +0.41% settles Dec 16
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $15.17 Now $14.73 −2.90% settles Dec 15
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $15.41 Now $14.73 −4.41% settles Dec 15
  4. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $14.84 Now $14.73 −0.74% settles Dec 4
  5. Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $14.84 Now $14.73 −0.74% settles Dec 4
  6. Nov 4, 202612d ago 144 Neutral 2/10 Entry $14.84 Now $14.73 −0.74% settles Dec 4
  7. Nov 3, 202613d ago 144 Neutral 2/10 Entry $15.95 Now $14.73 −7.65% settles Dec 3
  8. Nov 3, 202613d ago 8-K Bearish 5/10 Entry $15.95 Now $14.73 +7.65% settles Dec 3
  9. Nov 2, 202614d ago Insider Cluster Neutral 2/10 Entry $25.82 Now $14.73 −42.95% settles Dec 2
  10. Nov 2, 202614d ago 144 Neutral 2/10 Entry $25.82 Now $14.73 −42.95% settles Dec 2
Showing 10 of 33

US Market Status

Market Closed · Opens Wed (9h 32m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 8, 2026